Diagnostic and therapeutic approaches of mixed cryoglobulinemia in PITER (Piattaforma Italiana per lo studio della Terapia delle Epatiti viRali) cohort

Mixed cryoglobulinaemia: An important but frequently unrecognized and underestimated HCV‐related condition in the real life practice

“…These results, showed the real-life variability in the diagnostic approach to MC, suggesting, on the one hand, that MC prevalence in HCV+ individuals is generally underestimated, and, on the other hand, that the percentage of MC patients with CryoVas was probably overestimated in centres where MC is not routinely assessed.In the paper of Cacoub et al, the major studies that have reported a very good clinical profile for CryoVas treatment with DAAs are cited.The preliminary prospective results from 129 CryoVas treated patients included in PITER confirm the high clinical, immunological and virological effectiveness of DAA-based therapy in a large representative sample of these patients 3 (Table 1).Excluding the cost of antiviral treatment, the costs of CryoVas treatment cited in the study of Cacoub et al are higher than previous estimates for different severities of liver disease and also higher than the cost of patients with hospital admission because of liver failure complications. 4,5 In conclusion, available data stress the important economic burden of this syndrome and emphasize the importance of better management in order to decrease the clinical and economic consequences.…”

“…Excluding the cost of antiviral treatment, the costs of CryoVas treatment cited in the study of Cacoub et al are higher than previous estimates for different severities of liver disease and also higher than the cost of patients with hospital admission because of liver failure complications. 4,5 In conclusion, available data stress the important economic burden of this syndrome and emphasize the importance of better management in order to decrease the clinical and economic consequences.…”